Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 4859-4866

  You, Qi ^a   Yao, Yuan ^a   Zhang, Yuanlong ^b   Fu, Songbin ^c   Du, Mei ^d   Zhang, Guangmei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b Harbin Red Cross Central Hospital   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d Harbin Maternal and Child Health Care Hospital   (China)

Author keywords

Amniotic fluid; Mesenchymal stem cell; Ovarian cancer; Targeted therapy

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; RECOMBINANT INTERLEUKIN 2; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2;

ADULT; AMNIOTIC FLUID MESENCHYMAL STEM CELL; AMNIOTIC FLUID STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; FETUS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; RECOMBINANT PLASMID; SECOND TRIMESTER PREGNANCY; STABLE TRANSFECTION; TRANSIENT TRANSFECTION; AMNION FLUID; ANIMAL; APOPTOSIS; CELL MOTION; CYTOLOGY; DISEASE MODEL; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PLASMID;

AMNIOTIC FLUID; ANIMALS; APOPTOSIS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKIN-2; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PLASMIDS; TRANSFECTION;

EID: 84940501815     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4076     Document Type: Article

References (21)

1. Smolle E, Taucher V, Pichler M, Petru E, Lax S and Haybaeck J: Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci 14: 9536-9555, 2013.
2. Crallan RA, Georgopoulos NT and Southgate J: Experimental models of human bladder carcinogenesis. Carcinogenesis 27: 374-381, 2006.
3. You Q, Cai L, Zheng J, Tong X, Zhang D and Zhang Y: Isolation of human mesenchymal stem cells from third-trimester amniotic fuid. Int J Gynaecol Obstet 103: 149-152, 2008.
4. Waldmann TA: The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601, 2006.
5. Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D, Davey RT, Kovacs JA, et al: IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104: 775-780, 2004.
6. Tourani JM, Pfster C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, et al; Subcutaneous Administration Propeukin Program Cooperative Group: Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: Final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 21: 3987-3994, 2003.
7. Yang T, Wall EM, Milne K, Theiss P, Watson P and Nelson BH: CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism. Clin Cancer Res 13: 7172-7180, 2007.
8. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA, Kelley JL, Price FV and Edwards RP: A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 59: 293-301, 2010.
9. Lee JM, Yoon SH, Kim HS, Kim SY, Sohn HJ, Oh ST, Oh IH and Kim TG: Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. Cancer Gene Ther 17: 742-750, 2010.
10. Kang TH, Mao CP, He L, Tsai YC, Liu K, La V, Wu TC and Hung CF: Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specifc CD8+ T cells in the tumor loci and enhanced anti-tumor effects. PLoS One 7: e35141, 2012.
11. Le Page C, Génin P, Baines MG and Hiscott J: Interferon activation and innate immunity. Rev Immunogenet 2: 374-386, 2000.
12. Gao Y, Yao A, Zhang W, Lu S, Yu Y, Deng L, Yin A, Xia Y, Sun B and Wang X: Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepa-tocellular carcinoma in nude mice. Oncogene 29: 2784-2794, 2010.
13. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M and Godwin AK: Hereditary ovarian cancer: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3: 97-137, 2009.
14. Wei S, Kryczek I, Edwards R P, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, et al: Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor traffcking in patients with ovarian carcinoma. Cancer Res 67: 7487-7494, 2007.
15. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M and Lang FF: Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 69: 8932-8940, 2009.
16. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608, 2002.
17. Ren C, Kumar S, Chanda D, Chen J, Mountz JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26: 2332-2338, 2008.
18. Bexell D, Scheding S and Bengzon J: Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 18: 1067-1075, 2010.
19. Spaeth E, Klopp A, Dembinski J, Andreeff M and Marini F: Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15: 730-738, 2008.
20. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, et al: Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25: 100-106, 2007.
21. Ren C, Kumar S, Chanda D, Chen J, Mountz JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26: 2332-2338, 2008.